A new review and policy statement underscore the inaccuracy of sickle cell trait as a cause of death on autopsies.
Kyle Registre's childhood dream of becoming a pilot can finally come true now that he says he's been cured of sickle cell ...
Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
"People who suffer from sickle cell have challenges that I don't believe we all know," Philpart said. "Sometimes it gets lost ...
Right now, approximately 20 billion red blood cells are busy traveling through your blood vessels. They are delivering oxygen ...
Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.
In this article, we explore the experiences of sickle cell patients in emergency care and the ways they can advocate for themselves ...
Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.
Exagamglogene autotemcel (exa-cel) gene therapy offers a potential cure for severe sickle cell disease, now available on NHS.
New gene therapies could transform sickle cell treatment forever. A future without pain crises or hospitalizations may finally be within reach.